444 related articles for article (PubMed ID: 27838224)
21. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
[TBL] [Abstract][Full Text] [Related]
22. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
23. The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome.
Ally MS; Tang JY; Joseph T; Thompson B; Lindgren J; Raphael MA; Ulerio G; Chanana AM; Mackay-Wiggan JM; Bickers DR; Epstein EH
JAMA Dermatol; 2014 May; 150(5):542-5. PubMed ID: 24623282
[TBL] [Abstract][Full Text] [Related]
24. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
25. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
26. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
Alfieri S; Romanò R; Marceglia S; De Giorgi V; Peris K; Sollena P; Piccerillo A; Moro R; Gualdi G; Ascierto PA; Palla M; Paone M; Eibenschutz L; Spagnolo F; Queirolo P; Filippini DM; Cavalieri S; Resteghini C; Bergamini C; Manocchio A; Licitra L; Bossi P
Oncologist; 2024 May; 29(5):e699-e707. PubMed ID: 38127280
[TBL] [Abstract][Full Text] [Related]
27. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
[TBL] [Abstract][Full Text] [Related]
28. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
29. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
[TBL] [Abstract][Full Text] [Related]
31. Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series.
Wescott R; Samlowski W
Curr Oncol; 2023 Oct; 30(10):9156-9167. PubMed ID: 37887561
[TBL] [Abstract][Full Text] [Related]
32. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
33. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
[TBL] [Abstract][Full Text] [Related]
35. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
Kieny A; Kremer V; Scheidecker S; Lipsker D
Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
[No Abstract] [Full Text] [Related]
36. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
37. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
38. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
Bayers S; Kapp DL; Beer KR; Slavin B
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
40. Treatment of multiple unresectable basal cell carcinomas from Gorlin-Goltz syndrome: a case report.
Ojevwe FO; Ojevwe CD; Zacny JP; Dudek AZ; Lin A; Kohlitz P
Anticancer Res; 2015 Mar; 35(3):1777-81. PubMed ID: 25750342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]